SCHEDULE: Empery Asset Management Adjusts Annovis Bio Stake

Empery Asset Management, LP and Ryan M. Lane have filed an amendment to their Schedule 13G, reporting beneficial ownership of Annovis Bio, Inc. common stock at 4.99% after accounting for warrant exercise limitations.

Summary

• Empery Asset Management, LP and Ryan M. Lane have filed an amendment (Amendment No. 1) to their Schedule 13G filing concerning Annovis Bio, Inc.
• The filing reports beneficial ownership of 2,241,537 shares of Annovis Bio, Inc. common stock, representing 4.99% of the class.
• This ownership figure includes shares issuable upon exercise of warrants, subject to a 'Blocker' provision that prevents ownership exceeding 4.99%.
• The reporting persons cannot exercise all warrants due to this Blocker limitation.
• Empery Asset Management, LP acts as the investment manager for the Empery Funds, which hold the warrants.
• Ryan M. Lane is identified as the reporting individual, with investment discretion over the shares held by the Empery Funds.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership to just under the 5% threshold, indicating a potential reduction in stake or a strategic adjustment by the reporting entity without significant new operational or financial disclosures.

Positives

• The reporting persons maintain a significant stake in Annovis Bio, Inc., indicating continued interest.
• The ownership is reported just below the 5% threshold, which can offer flexibility in trading without triggering additional disclosure requirements.

Negatives

• The inability to exercise all warrants due to the 'Blocker' provision suggests potential limitations on fully realizing their investment or strategic options.
• The filing is an amendment to a previous filing, suggesting a change in beneficial ownership or reporting status, which could imply a reduction in stake or a rebalancing of holdings.

Risks

• The 'Blocker' provision limits the reporting persons' ability to exercise all warrants, potentially capping their upside or influence.
• The filing indicates that the reporting persons cannot exercise all warrants due to the Blocker, meaning their effective ownership is capped at 4.99%.

Future Outlook

The filing does not contain forward-looking statements or specific future guidance from the company. It pertains to the reporting of beneficial ownership by external entities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to report their holdings. This particular filing indicates a strategic position by Empery Asset Management, LP and Ryan M. Lane concerning Annovis Bio, Inc., likely related to their investment strategy and compliance with ownership thresholds.

Stakeholder Impact

• Shareholders: The filing may signal a shift in significant holdings, potentially influencing market perception, though the ownership is just below a key disclosure threshold.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership levels in Annovis Bio, Inc. and file amendments as required by SEC regulations.

Key Dates

Keywords

Annovis Bio, Schedule 13G, Beneficial Ownership, Warrants, Investment Management, Securities Exchange Act, Empery Asset Management, Ryan M. Lane